top of page
Bacterial-vaginosis-candidiasis_edited.jpg

THE FUTURE OF GYNAECOLOGICAL
HEALTH IS HERE

Revolutionary Biotechnological Solutions by Avodes

We’re Changing the Way the World Thinks About Vaginal Microbiome

7-1.png

OUR SOLUTIONS

We Deliver Exceptional Biotechnological Products

BIOTECHNOLOGICAL
SOLUTION

Our unique biotechnological peptides based treatment for Bacterial Vaginosis and Candidiasis selectively inhibits pathogens and protects Lactobacilli. We believe in treating gynaecological conditions without the use of antibiotics.

lactobacilli.jpg
woman-scientist.jpg

RESEARCH AND DEVELOPMENT

At Avodes Biotechnology, we are dedicated to research and development to provide the most innovative and effective biotechnological solutions. Our team of experts are constantly pushing the boundaries of biotechnology to find new and effective treatments for gynaecological conditions.

Bacterial Vaginosis

BV and VVC (Candidiasis) are the most common vaginal infections in women of childbearing age, including pregnant women. 1

35%

of people (age 15-44) with a vagina will get BV
each year. 2

38%

of people after menopause will get BV each year. 3

 up to 80%

Recurrence rate of BV 
within 12 months. 4

75%

of women will have at least one episode of
Vulvovaginal Candidiasis (VVC). 5

Antibiotics

are used to treat BV. At the same time, they cause Candidiasis:
Broad-spectrum antibiotics, which kill a range of bacteria, also kill healthy bacteria in your vagina, leading to overgrowth of yeast. 6

68%

of the G. vaginalis strains (one of the main bacteria causing BV)  are already resistant to metronidazole. 7

Why it is important to treat BV and VVC as soon as possible?

Bacterial Vaginosis and Vulvovaginal Candidiasis causes:

​

Premature Birth

Infertility

Miscarriage

Neonatal Meningitis

Cervical Cancer

bacterial-vaginosis-3_edited.jpg
bacterial-vaginosis.jpg

OUR COMMITMENT

Revolutionizing the Solutions for Gynaecological Conditions with Biotechnology

At Avodes Biotechnology, we are committed to revolutionizing the solutions for gynaecological conditions. We believe in using biotechnology to provide safe, effective, and innovative solutions that improve the lives of women.

Avodes PIPELINE

Indication

Research

Microbiological testings

Pre-Clinical

Clinical

Avodes Gel

BV and VVC treatment

rodykle-1.png

Avodes Sponge

BV and VVC treatment/ prevention

rodykle-1.png

Spomfy

Menstrual sponge

rodykle3.png
EU Project
EN_Co-fundedbytheEU_RGB_WHITE Outline.png

EU Project

I

"AvodÄ—s", JSC together with its partner "VaizduotÄ—", JSC is implementing the project "R&D for the development of innovative biotechnology based  treatment of Bacterial Vaginosis and Candidasis" No. 02-019-K-0018. During the project, R&D activities will address identified scientific uncertainties and develop an innovative product - Avodes gel for the treatment of Bacterial Vaginosis and Candidasis.

 

The project is being implemented according to the 2022-2030 Development Program managed by the Ministry of Economy and Innovation of the Republic of Lithuania, under the Economic Transformation and Competitiveness Development Program, progress measure No. 05-001-01-05-07 "Create a coherent system for promoting innovation," activity "Promote the supply of innovations," sub-activity "Invest in activities for the development of new high value-added products and create conditions for researchers to participate in company R&D activities, promote intellectual property, early-stage pilot production of newly created products, preparation for the market."

 

The total value of the project is EUR 1 552 734, with funding of EUR 1 190 492, financed by the European Regional Development Fund.

 

The project implementation period is from 2024-07-15 to 2026-07-15.

OUR PARTNERS

Avodes works with a range of partners in the healthcare industry to provide the best biotechnological solutions for the treatment of gynaecological conditions.

HEALTHCARE PROVIDERS

RESEARCH INSTITUTES

PHARMACEUTICAL COMPANIES

WOMEN'S HEALTHCARE ORGANIZATIONS

bottom of page